Ivacaftor in People with Cystic Fibrosis and a <i>3849+10kb C</i>→<i>T</i> or <i>D1152H</i> Residual Function Mutation.

"Author disclosures are available with the text of this article at www.atsjournals.org."

"AcknowledgmentThe authors thank the people with cystic fibrosis and their families for their contributions to the trial. They also thank the physicians from all Israeli cystic fibrosis centers, especially Professor Lea Bentur, Professor Hannah Blau, Dr. Huda Mussaffi, Dr. Michal Shteinberg, Dr. Galit Livnat, Professor Ori Efrati, and Professor Micha Aviram for referring their patients to the study. Hanna Leah Cohen-Knafou, Dinah Barros, and Hava Berros of the Hadassah Cystic Fibrosis Center were responsible for carrying out all study-related procedures. The authors thank Sylvia Boj, Ph.D., Jasper Mullenders, Ph.D., and the other members of Hubrecht Organoid Technology for their assistance with the organoid technology. Editorial coordination and support were provided by Tejendra R. Patel, Pharm.D., of Vertex Pharmaceuticals Inc. Medical writing and editorial support were provided by JoAnna Anderson, Ph.D., and Amos Race, Ph.D., of ArticulateScience LLC, which received funding from Vertex Pharmaceuticals Inc. Supported by Vertex Pharmaceuticals Inc., which also participated in the design, statistical analysis, and interpretation of the data, and provided editorial and writing assistance."

"Clinical trial registered with ClinicalTrials.gov (NCT03068312)."